Market Overview:
The global recombinant human interferon market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hepatitis B, hepatitis C, and multiple sclerosis (MS) across the globe. In addition, rising demand for recombinant human interferon products owing to their superior efficacy and safety profiles is also contributing significantly to the growth of this market. On the basis of type, gamma inhibitors accounted for a major share of the global recombinant human interferon market in 2017. This segment is expected to maintain its dominance during the forecast period as well due to high demand for these products across various applications such as hepatitis B, hepatitis C, MS, and others.
Product Definition:
A recombinant human interferon is a protein that is produced by genetically engineered bacteria. It can be used to treat certain types of cancer, hepatitis C, and other diseases.
Gamma Inhibitors:
The growth factor in the recombinant human interferon market is driven by factors such as rising incidences of cancer, increasing prevalence of viral diseases and autoimmune disorders. The other drivers for this market are growing demand for new treatment methods and continuous research & development activities.
According to the World Health Organization (WHO), around 8 million people die each year due to cancer, out of which more than 6 million people die due to non-communicable diseases.
Alpha Inhibitors:
Alpha inhibitors are a group of drugs that competitively inhibit the activity of Alpha-1 antitrypsin. They have been used in the treatment of various respiratory disorders, including bronchitis and emphysema. The mechanism by which they act is not completely understood but it is believed that they work by decreasing inflammation caused by lung cells.
Application Insights:
The application segment includes hepatitis B, hepatitis C, multiple sclerosis and others. Hepatitis B dominated the global market in terms of revenue in 2017 owing to the presence of a large patient base susceptible to infection with HBV. The introduction of new products and potential approval for commercial use are expected to drive the product demand over the forecast period.
Recombinant human interferon gamma is used for treatment purposes against hepatitis C virus (HCV) infection worldwide due to its ability to reduce liver inflammation as well as hepatocellular carcinoma (HCC). However, there are no approved drugs available for HCV treatment yet; therefore, companies focus on research & development activities regarding this end-stage liver disease.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, high patient awareness levels coupled with relatively higher healthcare expenditure in this region are some factors that can be attributed to its continued dominance over the forecast period. Asia Pacific is expected to grow at an exponential rate during the forecast period owing to increasing government initiatives for raising public awareness regarding available treatment options, rising disposable income along with growing demand for cost-effective therapies are some factors anticipated to drive growth during the forecast period. Moreover, improving healthcare infrastructure and economic development will also help boost growth over the coming years.
Growth Factors:
- Increasing incidence of chronic diseases such as cancer, hepatitis, and HIV/AIDS is expected to drive the demand for recombinant human interferon over the forecast period.
- Growing awareness about the benefits of recombinant human interferon therapy is anticipated to propel market growth.
- Rising number of clinical trials for recombinant human interferon is projected to fuel market growth in the near future.
- Technological advancements in manufacturing process are likely to provide impetus to market growth over the next few years. 5) increasing demand from emerging economies is expected to create new opportunities for players operating in this market over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Interferon Market Research Report
By Type
Gamma Inhibitors, Alpha Inhibitors, Others
By Application
Hepatitis B, Hepatitis C, Multiple Sclerosis, Others
By Companies
Roche, Merck, Bayer, Biogen Idec, Gensci, Huaxin, Triprime, Sinovac, Zhaoke, Kawin, Roche, R&D Systems, Thermo Fisher Scientific, BioLegend, Invitrogen, OriGene, Biorbyt
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
172
Number of Tables & Figures
121
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Interferon Market Report Segments:
The global Recombinant Human Interferon market is segmented on the basis of:
Types
Gamma Inhibitors, Alpha Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis B, Hepatitis C, Multiple Sclerosis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Merck
- Bayer
- Biogen Idec
- Gensci
- Huaxin
- Triprime
- Sinovac
- Zhaoke
- Kawin
- Roche
- R&D Systems
- Thermo Fisher Scientific
- BioLegend
- Invitrogen
- OriGene
- Biorbyt
Highlights of The Recombinant Human Interferon Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gamma Inhibitors
- Alpha Inhibitors
- Others
- By Application:
- Hepatitis B
- Hepatitis C
- Multiple Sclerosis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Interferon Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human interferon (rhI) is a type of cytokine that is produced in a laboratory by recombining the DNA of two different types of cells. RhI helps to fight against infection by viruses, bacteria, and other parasites.
Some of the major players in the recombinant human interferon market are Roche, Merck, Bayer, Biogen Idec, Gensci, Huaxin, Triprime, Sinovac, Zhaoke, Kawin, Roche, R&D Systems, Thermo Fisher Scientific, BioLegend, Invitrogen, OriGene, Biorbyt.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Human Interferon Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Human Interferon Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Human Interferon Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Human Interferon Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Human Interferon Market Size & Forecast, 2018-2028
4.5.1 Recombinant Human Interferon Market Size and Y-o-Y Growth
4.5.2 Recombinant Human Interferon Market Absolute $ Opportunity
Chapter 5 Global Recombinant Human Interferon Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Human Interferon Market Size Forecast by Type
5.2.1 Gamma Inhibitors
5.2.2 Alpha Inhibitors
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Human Interferon Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Human Interferon Market Size Forecast by Applications
6.2.1 Hepatitis B
6.2.2 Hepatitis C
6.2.3 Multiple Sclerosis
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Human Interferon Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Human Interferon Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Human Interferon Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Human Interferon Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Human Interferon Market Size Forecast by Type
9.6.1 Gamma Inhibitors
9.6.2 Alpha Inhibitors
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Human Interferon Market Size Forecast by Applications
9.10.1 Hepatitis B
9.10.2 Hepatitis C
9.10.3 Multiple Sclerosis
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Human Interferon Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Human Interferon Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Human Interferon Market Size Forecast by Type
10.6.1 Gamma Inhibitors
10.6.2 Alpha Inhibitors
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Human Interferon Market Size Forecast by Applications
10.10.1 Hepatitis B
10.10.2 Hepatitis C
10.10.3 Multiple Sclerosis
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Human Interferon Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Human Interferon Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Human Interferon Market Size Forecast by Type
11.6.1 Gamma Inhibitors
11.6.2 Alpha Inhibitors
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Human Interferon Market Size Forecast by Applications
11.10.1 Hepatitis B
11.10.2 Hepatitis C
11.10.3 Multiple Sclerosis
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Human Interferon Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Human Interferon Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Human Interferon Market Size Forecast by Type
12.6.1 Gamma Inhibitors
12.6.2 Alpha Inhibitors
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Human Interferon Market Size Forecast by Applications
12.10.1 Hepatitis B
12.10.2 Hepatitis C
12.10.3 Multiple Sclerosis
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Human Interferon Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Human Interferon Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Human Interferon Market Size Forecast by Type
13.6.1 Gamma Inhibitors
13.6.2 Alpha Inhibitors
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Human Interferon Market Size Forecast by Applications
13.10.1 Hepatitis B
13.10.2 Hepatitis C
13.10.3 Multiple Sclerosis
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Human Interferon Market: Competitive Dashboard
14.2 Global Recombinant Human Interferon Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Merck
14.3.3 Bayer
14.3.4 Biogen Idec
14.3.5 Gensci
14.3.6 Huaxin
14.3.7 Triprime
14.3.8 Sinovac
14.3.9 Zhaoke
14.3.10 Kawin
14.3.11 Roche
14.3.12 R&D Systems
14.3.13 Thermo Fisher Scientific
14.3.14 BioLegend
14.3.15 Invitrogen
14.3.16 OriGene
14.3.17 Biorbyt
